COVID-2019 Alert

Information about the 2019 Novel Coronavirus. Read the latest >

Información sobre el coronavirus 2019 (COVID-19). Aprenda más >


John Yost, MD

  • No Image



Work and Education

Professional Education

University of Michigan Medical School, Ann Arbor, MI, 5/14/2010


Oakwood Hospital and Medical Center, Dearborn, MI, 6/30/2011


New York University Dermatology Residency, New York, NY, 6/30/2014

Board Certifications

Dermatology, American Board of Dermatology

All Publications

Pernio-like eruption associated with COVID-19 in skin of color. JAAD case reports Daneshjou, R., Rana, J., Dickman, M., Yost, J. M., Chiou, A., Ko, J. 2020; 6 (9): 89297

View details for DOI 10.1016/j.jdcr.2020.07.009

View details for PubMedID 32835046

Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With > 50% Baseline Infection JOURNAL OF DRUGS IN DERMATOLOGY Pariser, D. M., Wendelken, M. E., Rycerz, A. M., Lowe, N., Yost, J., Lipner, S. R. 2018; 17 (2): 16872


Women with onychomycosis may suffer more effects on their quality of life than men. There is limited female-specific data on the treatment of onychomycosis. Tavaborole is a topical treatment option for onychomycosis. This post-hoc study evaluated the nail plates of women using data from the tavaborole 5% Phase III studies at baseline and end of study for the areas of healthy nail and infected nail. Over 52 weeks (48-week treatment, 4-week follow up), women treated with tavaborole had an average 32% increase in healthy nail and 21% decrease in infected nail. Patients with baseline infection involving >50% of the nail plate had an average increase in percentage of unaffected nail surface area of 81% and a corresponding 51% decrease in infected nail. These analyses suggest that patients with the greatest toenail involvement at baseline had greater overall improvements than those who were less affected. This evaluation provides additional clinical guidance for treating women with onychomycosis using tavaborole. J Drugs Dermatol. 2018;17(2):168-172.

View details for Web of Science ID 000424534100005

View details for PubMedID 29462224

Neurogenic Rosacea: A Distinct Clinical Subtype Requiring a Modified Approach to Treatment ARCHIVES OF DERMATOLOGY Scharschmidt, T. C., Yost, J. M., Truong, S. V., Steinhoff, M., Wang, K. C., Berger, T. G. 2011; 147 (1): 123-126

View details for Web of Science ID 000286229000035

View details for PubMedID 21242409